Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

Clinical trial NCT00688090 · COMPLETED

Trial details

NCT number: NCT00688090
Sponsor: Mannkind Corporation
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Melanoma Stage III and IV Melanoma

Start date: 2008-06-01
Primary completion: 2009-12-01
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.